Hye Jin Kang,1,7 Brian E. Krumm,2,7 Adrien Tassou,3,7 Matan Geron,3,7 Jeffrey F. DiBerto,2,9 Nicholas J. Kapolka,2,9 Ryan H. Gumpper,2 Kensuke Sakamoto,2 D. Dewran Kocak,2 Reid H.J. Olsen,2,8 Xi-Ping Huang,2,4 Shicheng Zhang,2 Karen L. Huang,3 Saheem A. Zaidi,5 My V. T. Nguyen,5 Min Jeong Jo,1 Vsevolod Katritch,5 Jonathan F. Fay,6 Gre´ gory Scherrer,3,* and Bryan L. Roth 2,10,*
1Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea
2Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
3Department of Cell Biology and Physiology, UNC Neuroscience Center, Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
4National Institute of Mental Health Psychoactive Drug Screening Program (NIMH-PDSP), School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
5Department of Quantitative and Computational Biology, Department of Chemistry, Center for New Technologies in Drug Discovery and Development, Bridge Institute, Michelson Center for Convergent Biosciences, University of Southern California, Los Angeles, CA, USA
6Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, Baltimore, MD 21201, USA
7These authors contributed equally
8Present address: Cellular Pharmacology, Exscientia, Oxford, UK
9Present address: EvE Bio LLC, Durham, NC 27703, USA
10Lead contact
*Corresponding authors: correspondence to Gre´ gory Scherrer or Bryan L. Roth